PATENT CLAIM ANALYSIS

Application Number: 15910610
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-11
Patent Classification: ["424", "093700"]

Abstract:
Autologous bone marrow cells (BMC) are transplanted to a heterologous site in a patient after a sample of the patient's BMC has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation. The phenotypic profile may be obtained by screening a sample of bone marrow cells (BMC) from the patient for the phenotypic profile, such as a CD profile, the phenotype profile may be assessed to determine the likelihood that the BMC will be suitable for transplantation to the heterologous tissue site without enriching particular phenotypic population(s) of the BMC.

Claim (Index 4):
A method as in  claim 2 , wherein the concentrations comprise threshold concentrations of 21,000 CD34+ cells, 9,500 CD133+ cells, and 19,000 CD19+ cells.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 90.0
- Lexical Diversity: 1.81356
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15693679', '12966401', '10589173', '13905526', '10574380']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7031919317727308
- 35 USC 102 Novelty (BERT): 0.6503127132462936
- Combined Prediction Score: 0.697904009920087
- Mean Citation Score: 354.995042
- Max Citation Score: 625.4530599999998
- Similarity Product: 575.311957258675

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test